CHRISTOPHER MYERS: Open Payments
NPI 1003905670 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,233 in 157 payments from 13 companies in 2025. Trend: 2023 $1,570 · 2024 $1,462 · 2025 $2,233
Food & beverage: $2,094Education: $139
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 59 | $561 |
| E.R. Squibb & Sons, L.L.C. | 20 | $382 |
| Janssen Pharmaceuticals, Inc | 18 | $291 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $219 |
| Alkermes, Inc. | 8 | $187 |
| Vanda Pharmaceuticals Inc. | 11 | $187 |
| Otsuka America Pharmaceutical, Inc. | 15 | $167 |
| Neurocrine BioSciences, Inc. | 5 | $82 |
| Lundbeck LLC | 4 | $64 |
| Noven Therapeutics, LLC | 2 | $39 |
Products named: UZEDY, COBENFY, CAPLYTA, INVEGA SUSTENNA, ARISTADA, REXULTI, HETLIOZ, SPRAVATO.
Industry payments across NC — which companies pay providers there.
